Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
P., Kuks, J
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
BPC-157 (Body Protection Compound-157) Purported Benefits: Accelerated wound healing Reduced inflammation Improved joint and gut health Potential Risks and Complications: Unknown Long-Term Effects: With limited human studies, the long-term impact on organs and systems is unknown
At a glance Key benefits What patients value about BPC 157
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 29.59
US$ 24.45
/assets/images/provider/photos/2805921.jpeg)
US$ 26.46
